Innohep (Tinzaparin Sodium)

Tinzaparin sodium binds to antithrombin III, markedly enhancing its inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This selective inhibition reduces thrombin generation, limits fibrin formation, and thereby prevents the development and propagation of pathological blood clots.

The dosing regimen for Innohep is individualized and determined by the prescribing clinician based on the specific indication, patient weight, renal function, and risk factors. Healthcare professionals calculate the appropriate subcutaneous dose and duration according to current clinical guidelines.

Safety data for tinzaparin sodium in pregnancy and lactation are limited. It should be used during pregnancy only if the potential maternal benefit outweighs any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in breast milk.

To order Innohep, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and assists with import documentation.

Both Innohep (tinzaparin) and enoxaparin are low molecular weight heparins, but tinzaparin has a slightly longer half‑life and a higher anti‑Xa to anti‑IIa activity ratio. Clinical studies suggest comparable efficacy for venous thromboembolism prophylaxis, while dosing frequency and monitoring requirements may differ based on renal function and patient characteristics.

Innohep vials must be stored at 2‑8 °C (refrigerated) and protected from light. Do not freeze or shake the product. Before use, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic technique when preparing the subcutaneous injection.

Innohep is administered by subcutaneous injection, typically into the abdominal wall or thigh. The injection site should be rotated to minimize local irritation. Healthcare professionals prepare the dose using a sterile syringe, ensuring proper aseptic technique, and educate patients on self‑administration if appropriate.

The most serious risks include major bleeding events such as intracranial or gastrointestinal hemorrhage, and heparin‑induced thrombocytopenia (HIT), which can paradoxically cause thrombosis. Patients should be monitored for signs of excessive bleeding, sudden drops in platelet count, or new thrombotic complications.

Innohep is contraindicated in patients with known hypersensitivity to tinzaparin or any component of the formulation, active major bleeding, or a history of heparin‑induced thrombocytopenia. Caution is also advised for individuals with severe renal impairment, uncontrolled hypertension, or those scheduled for neuraxial anesthesia without appropriate discontinuation.